AstraZeneca Profit Beats Estimates as Forecast Remains Unchanged

AstraZeneca Profit Beats Estimates as Forecast Remains Unchanged

JB Reed/Bloomberg

AstraZeneca’s second-best-selling drug, Seroquel for schizophrenia, lost U.S. patent protection in March, while the patent on Nexium for ulcers, the third-biggest seller, expires in the U.S. in 2014.